{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:08:05Z","timestamp":1784552885506,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tacrolimus is a first-line immunosuppressant used in kidney transplantation. However, its narrow therapeutic window and variable exposure present challenges. Extended- and prolonged-release formulations, ER-tacrolimus (Advagraf) and LCP-tacrolimus (Envarsus), respectively, improve adherence, and LCP-tacrolimus provides higher bioavailability. The safety and benefits of switching from ER-tacrolimus to LCP-tacrolimus were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In this open-label switch study, first-time, adult, kidney transplant recipients with stable graft function, therapeutic ER-tacrolimus levels, and rapid metabolizer status (C\/D ratio &lt;1.05) were switched to LCP-tacrolimus, followed by reconversion to ER-tacrolimus after 3 weeks. The primary outcome was the dose required to maintain therapeutic trough levels; secondary outcomes included differences in adverse effects, pill burden, patient preference, and pharmacokinetics (tacrolimus trough concentration, C\n                      <jats:sub>0<\/jats:sub>\n                      ; peak blood levels, Cmax; area under the concentration\u2013time curve, AUC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twelve patients were included. The dose to achieve therapeutic C\n                      <jats:sub>0<\/jats:sub>\n                      (5\u20138 \u00b5g\/L) was 30% lower with LCP-tacrolimus than with ER-tacrolimus (6.0 mg versus 8.5 mg,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004), with similar pill burden and adverse effects. AUC or Cmax were similar [LCP-tac: 14.75 (11.68\u201316.27); ER-tac: 17.15 (13.53\u201320.93)]. For CYP3A5 expressors (n = 7; 58%), there was a stronger correlation between C\n                      <jats:sub>0<\/jats:sub>\n                      and AUC for LCP-tacrolimus (0.85,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.016; 0.43,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.34, respectively). No serious adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Conversion to LCP-tacrolimus with a 30% dose reduction achieved therapeutic C\n                      <jats:sub>0<\/jats:sub>\n                      without differences in pill burden or overall exposure. In the CYP3A5 expressors, C\n                      <jats:sub>0<\/jats:sub>\n                      was more strongly correlated with exposure to LCP-tacrolimus, suggesting more reliable trough monitoring. The small sample size, short follow-up period, and selection bias limit interpretation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001511","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:00:15Z","timestamp":1784552415000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Extended-Release Tacrolimus Versus LifeCycle Pharma Tacrolimus in Kidney Transplant Recipients: A Switch Study"],"prefix":"10.1097","author":[{"given":"Nienke A.","family":"Manson","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Nephrology, Amsterdam University Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7963-8658","authenticated-orcid":false,"given":"Emma H. C.","family":"van Schijndel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nephrology, Amsterdam University Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora S. M.","family":"Standaar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nephrology, Amsterdam University Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"Vos-van der Meer","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy & Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liffert","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nephrology, Amsterdam University Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A. A.","family":"Mathot","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy & Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Maizaud","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc L.","family":"Hilhorst","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nephrology, Amsterdam University Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike J.","family":"Bemelman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nephrology, Amsterdam University Medical Center, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"R1-20260720","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00003495-200059020-00021","article-title":"Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation","volume":"59","author":"Plosker","year":"2000","journal-title":"Drugs"},{"key":"R2-20260720","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","article-title":"A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years","volume":"73","author":"Vincenti","year":"2002","journal-title":"Transplantation"},{"key":"R3-20260720","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin Pharmacokinet."},{"key":"R4-20260720","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"R5-20260720","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R6-20260720","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3390\/jcm8101586","article-title":"A low tacrolimus concentration\/dose ratio increases the risk for the development of acute calcineurin inhibitor-induced nephrotoxicity","volume":"8","author":"Tholking","year":"2019","journal-title":"J Clin Med."},{"key":"R7-20260720","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/ndt\/gfq096","article-title":"High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation","volume":"25","author":"Borra","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"R8-20260720","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation","volume":"19","author":"Yu","year":"2018","journal-title":"Curr Drug Metab."},{"key":"R9-20260720","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.105.003822","article-title":"CYP3A5 genetic polymorphisms in different ethnic populations","volume":"33","author":"Roy","year":"2005","journal-title":"Drug Metab Dispos."},{"key":"R10-20260720","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e3182725532","article-title":"Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring","volume":"95","author":"Kuypers","year":"2013","journal-title":"Transplant J."},{"key":"R11-20260720","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/01.TP.0000437561.31212.0e","article-title":"Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation","volume":"97","author":"Stifft","year":"2014","journal-title":"Transplantation"},{"key":"R12-20260720","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1586\/1744666X.2014.983903","article-title":"Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations","volume":"10","author":"Grinyo","year":"2014","journal-title":"Expert Rev Clin Immunol."},{"key":"R13-20260720","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.ajkd.2015.10.024","article-title":"Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of Phase 3, double-blind, randomized trial","volume":"67","author":"Rostaing","year":"2016","journal-title":"Am J Kidney Dis."},{"key":"R14-20260720","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1111\/j.1600-6143.2010.03256.x","article-title":"Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study","volume":"10","author":"Kramer","year":"2010","journal-title":"Am J Transplant."},{"key":"R15-20260720","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40262-015-0282-2","article-title":"Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients","volume":"54","author":"Staatz","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"R16-20260720","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ajt.13935","article-title":"A steady-state head-to-head pharmacokinetic comparison of all FK-506 (Tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study","volume":"17","author":"Tremblay","year":"2017","journal-title":"Am J Transplant."},{"key":"R17-20260720","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/ajt.12035","article-title":"Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial","volume":"13","author":"Bunnapradist","year":"2013","journal-title":"Am J Transplant."},{"key":"R18-20260720","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.phrs.2017.12.005","article-title":"Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients","volume":"129","author":"Marquet","year":"2018","journal-title":"Pharmacol Res."},{"key":"R19-20260720","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/FTD.0000000000000503","article-title":"Pharmacokinetic therapeutic drug monitoring of Advagraf in more than 500 adult renal transplant patients, using an expert system online","volume":"40","author":"Marquet","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R20-20260720","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40262-017-0533-5","article-title":"Population pharmacokinetics and Bayesian estimators for refined dose adjustment of a new tacrolimus formulation in kidney and liver transplant patients","volume":"56","author":"Woillard","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R21-20260720","doi-asserted-by":"crossref","first-page":"11366","DOI":"10.3389\/ti.2023.11366","article-title":"Tacrolimus exposure before and after a switch from twice-daily immediate-release to once-daily prolonged release tacrolimus: the ENVARSWITCH study","volume":"36","author":"Monchaud","year":"2023","journal-title":"Transpl Int."},{"key":"R23-20260720","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/ndt\/gfg381","article-title":"Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation","volume":"18","author":"Anglicheau","year":"2003","journal-title":"Nephrol Dial Transpl."},{"key":"R24-20260720","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"R25-20260720","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.3390\/jcm10245793","article-title":"The relationship between initial tacrolimus metabolism rate and recipients body composition in kidney transplantation","volume":"10","author":"Kolonko","year":"2021","journal-title":"J Clin Med."},{"key":"R26-20260720","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/bcp.15662","article-title":"Impact of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation","volume":"89","author":"Hirai","year":"2023","journal-title":"Br J Clin Pharmacol."},{"key":"R27-20260720","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/ctr.12581","article-title":"Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study","volume":"29","author":"Langone","year":"2015","journal-title":"Clin Transplant."},{"key":"R28-20260720","doi-asserted-by":"crossref","first-page":"18","DOI":"10.15586\/jrenhep.2020.68","article-title":"Conversion from extended-dose-release tacrolimus to Melt-dose tacrolimus in high metabolizer patients: is the new formulation of LPCT the best option for high metabolizer kidney transplanted patients?","volume":"4","author":"Carta","year":"2020","journal-title":"J Renal Hepatic Disord."},{"key":"R29-20260720","doi-asserted-by":"crossref","first-page":"e13767","DOI":"10.1111\/ctr.13767","article-title":"Effectiveness and safety of the conversion to MeltDose\u00ae extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: a retrospective study","volume":"34","author":"Sanchez Fructuoso","year":"2020","journal-title":"Clin Transpl."},{"key":"R30-20260720","doi-asserted-by":"crossref","first-page":"11571","DOI":"10.3389\/ti.2024.11571","article-title":"Impact of switching from immediate- or prolonged-release to once-daily extended-release tacrolimus (LCPT) on tremor in stable kidney transplant recipients: the observational ELIT study","volume":"37","author":"Giral","year":"2024","journal-title":"Transpl Int."},{"key":"R31-20260720","doi-asserted-by":"crossref","first-page":"e1612","DOI":"10.1097\/TXD.0000000000001612","article-title":"Modifying tacrolimus-related toxicity after liver transplantation comparing Life Cycle Pharma tacrolimus versus extended-released tacrolimus: a multicenter, randomized controlled trial","volume":"10","author":"Mulder","year":"2024","journal-title":"Transplant Direct"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:00:19Z","timestamp":1784552419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001511","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"2026-04-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}